• The U.S. Supreme Court has temporarily reinstated mail delivery of the abortion pill mifepristone.
• Justice Samuel Alito's order pauses a previous ruling from the 5th Circuit that restricted access.
• This decision allows telehealth prescriptions and mail delivery to continue at least until May 11.
• The legal battle stems from Louisiana's lawsuit challenging the FDA's regulations on mifepristone.
• Most abortions in the U.S. are currently performed via medication, predominantly using mifepristone.

On May 4, 2026, the U.S. Supreme Court temporarily lifted a ban on the mail delivery of mifepristone, one of the primary medications used for abortion. This ruling, issued by Justice Samuel Alito, pauses a lower court's decision until at least May 11, giving the court time to review legal challenges from two manufacturers of the drug, Danco Laboratories and GenBioPro, regarding the prescription and delivery methods for mifepristone. The 5th U.S. Circuit Court of Appeals had previously ruled that delivery should require in-person clinician visits, significantly narrowing access to the medication, according to Reuters, CBS News, and SCMP.

This interim order by the Supreme Court restores conditions allowing mifepristone to be prescribed through telehealth and mailed directly to patients, a practice that has been pivotal since the COVID-19 pandemic. The 5th Circuit's ruling that impeded these access points came at a time when states like Louisiana seek to increase restrictions on abortion access as a political maneuver, citing concerns about drug safety that the FDA has consistently rejected. The conflict has put the issue of reproductive rights back in the spotlight as upcoming elections approach, according to Le Monde, NPR, and Al Jazeera.

The legal arguments being made reflect the ongoing battle surrounding abortion rights and the accessibility of reproductive health services in the U.S. Since the Supreme Court's 2022 decision to overturn Roe v. Wade, several states have enacted stringent bans, leading to heightened tensions around medication abortion. The current litigation emphasizes political motivations behind such restrictions, demonstrating a split in approach between states that support access to reproductive health via telehealth and those that seek to instate more barriers, as highlighted in reports from Los Angeles Times, Reuters, and CBS News.